Skip to content

Public FDA record

Z-1548-2026: Owner's Booklets and Instructions for Use that are used with the following blood glucose measuring device

Recall record Z-1548-2026 for Trividia Health, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1548-2026
Company in FDA record
Trividia Health, Inc.
FDA classification date
Mar 12, 2026
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

The system labeling (user manual and online labeling) did not provide adequate directions for lay users to act on the E-5 error code. The error code description and recommended actions for the E-5 error code in the labeling do not: (a) clearly emphasize that an E-5 error code could represent a very high blood glucose level, and (b) prominently convey the appropriate immediate actions, such as contacting a healthcare professional. This could lead to a delay in treatment if the user does not seek medical attention immediately when receiving an E-5 error code and experiencing symptoms of high glucose.

Source facts

Action
On 2/6/2026, press was issued and correction notices were emailed to customers. E-5 Error Code in the Messages section of the Owner's Booklets/System Instructions for Use emphasizes that users must seek medical attention immediately if they receive an E-5 error code and are experiencing symptoms of high glucose. Customers: notify your customers immediately of the correction and to include the letter in their notification, and to ask that they notify their customers or facilities if they have further distributed the Products. Retail pharmacies: post the notice in areas where the Products are sold to notify patients. Multiple Patient Facilities: post the notice in areas where the Products are stored to notify personnel. People with Diabetes are asked to follow the updated E-5 error code instructions Visit www.trividiahealth.com for updated Owner's Booklets and help resources. Complete and return the acknowledgement form via email to trividia0126CS@trividiahealth.com Firm Customer Care Department: 1-888-835-2723, trividia0126CC@trividiahealth.com or visit www.trividiahealth.com/E-5productnotice , which has links to Owner's Booklets, correction notice, and press. On 5/5/2026, updated correction notices were mailed to customers informing them of the following: For people with diabetes, if possible, consider transitioning to an alternative method of testing your blood glucose. People with Diabetes who rely on intensive insulin therapy, sulfonylureas, or glucose monitoring due to frequent hypo- or hyperglycemia events should consider transitioning to an alternative testing method until the updated devices with updated software becomes available. Firm will notify users when the upgrade program becomes available. The firm asked customers to handle dissemination of the updated notice and completion/return of the acknowledgement form as stated above. Affected serial number search tool is located at www.trividiahealth.com/E-5productnotice
Initiated
2026-02-06
Root cause
Software design
Distribution
Worldwide distribution - US Nationwide including Puerto Rico and the countries of Mexico, United Kingdom, Jamaica, Trinidad & Tobago, and Australia.
Recall number
Z-1548-2026
Recall status
Open, Classified
CDRH record ID
218694
FDA classified
2026-03-12
Recall event number
98317

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗